Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
MyPeBS is an international randomized, open-label, multicentric, study assessing the effectiveness of a risk-based breast cancer screening strategy (using clinical risk scores and polymorphisms) compared to standard screening (according to the current national guidelines in each participating country) in detecting stage 2 or higher breast cancers.
Women will be differentially screened for 4 years and then, after an end-of-study mammogram, they will return to the routine screening practice. The main study endpoint will be measured at the end of the four years of intervention.
Furthermore, follow up data will be collected for 15 years from study entry for evaluation of long-term cumulative breast cancer incidence and breast cancer-specific survival
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard arm | Other | Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly. |
|
| Risk-based arm | Experimental | Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mammogram | Other | Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence rate of stage 2 and plus breast cancer (non-inferiority analysis) | The study primary objective is to show non-inferiority of the risk-stratified screening strategy in terms of incidence rate of breast cancer of stage 2 and higher (2+), compared to standard screening. | 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence rate of stage 2 and plus breast cancer (superiority analysis) | The key secondary objective, if non-inferiority is shown, is to demonstrate superiority of the risk-based screening arm to reduce the incidence rate of stage 2+ breast cancer, compared to standard screening. | 4 years |
| Rate of morbidity in each arm |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suzette DELALOGE, MD | Gustave Roussy - FRANCE | Study Chair |
| Paolo GORGIO-ROSSI, MD | Arcispedale Santa Maria Nuova-IRCCS - ITALY | Principal Investigator |
| Corinne BALLEYGUIER, MD | Gustave Roussy - FRANCE | Principal Investigator |
| Michal GUINDY, MD | ASSUTA Hospital - ISRAEL | Principal Investigator |
| Jean-Benoit BURRION, MD | Institut Jules Bordet - BELGIUM | Principal Investigator |
| Fiona GUILBERT, MD | University of Cambridge - UK | Principal Investigator |
| Marta ROMÁN, PhD | PSMAR - SPAIN | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Jules Bordet | Brussels | Belgium | ||||
| Gustave roussy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40089664 | Derived | Roux A, Hervouet L, Stefano FD, French DP, Giordano L, Ritchie D, Bugat MR, Keatley D, Cholerton R, McWilliams L, Rossi PG, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Roman M, Vissac-Sabatier C, Couch D, Delaloge S, Montgolfier S; MyPeBS Investigators and the MyPeBS Consortium. Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study. BMC Cancer. 2025 Mar 15;25(1):483. doi: 10.1186/s12885-025-13848-z. | |
| 35524202 |
| Label | URL |
|---|---|
| Public website of MyPeBS | View source |
Not provided
Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.
The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.
Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.
Not provided
| ID | Term |
|---|---|
| D019220 | High-Energy Shock Waves |
| ID | Term |
|---|---|
| D000069453 | Ultrasonic Waves |
| D013016 | Sound |
| D011840 | Radiation, Nonionizing |
| D011827 | Radiation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ultrasound | Other | As required according to the national/regional guidelines or personalised schedule according to risk assessment |
|
| MRI | Other | As required according to the national/regional guidelines or personalised schedule according to risk assessment |
|
| Tomosynthesis | Other | As required according to the national/regional guidelines or personalised schedule according to risk assessment |
|
Morbidity is defined as false positive imaging findings and benign breast biopsies |
| 4 years |
| Subject anxiety in response to risk evaluation | Subject anxiety will be evaluated using the State-Trait Anxiety Inventory (STAI) questionaire, and compared between treatment arms | 4 years |
| Socio-psychological characteristics of subjects | Socio-psychological characteristics will be evaluated using study specific questions concerning comprehension, information-seeking behavior, satisfaction and socio-demographic and economic status | 4 years |
| Subject quality of life | Subject quality of life will be evaluated using the EQ-5D quality of life questionnaire | 4 years |
| Comparison of cost-effectiveness of each strategy | Crude costs, defined as full real costs per stage 2 cancer diagnosis, will be estimated in each arm. The cost-effectiveness of mammographic screening will be calculated by comparing estimated life-years and costs of breast cancer in each arm | 4 years |
| Incidence of stage-specific breast cancer in each arm (including DCIS) | Comparison of the overall incidence of breast cancer detected in each arm according to AJCC stage | 4 years |
| Estimates of the rate of detection of clinically non-significant tumours (overdiagnosis) in each study arm | Overdiagnosed breast cancer cases are defined as cancers that would never have been detected clinically, if women had not been screened. Differential overdiagnosis will be measured comparing the cumulative incidence of breast cancer in each arm 15 years after the end of the interventional period of the study. | 15 years |
| Rate of false negative images and interval cancers in each arm | False negative images: in case of diagnosis of breast cancer in women whose last screening images (including mammogram +/- US and MRI) were considered as Breast Imaging- Reporting and Data System 1 or 2 (BI-RADS 1 or 2) at 6 months maximum before diagnosis. Interval cancers are defined as a breast cancers diagnosed between a negative screening episode - [mammogram classified as normal (BI-RADS ACR 1 or 2 or equivalent) or abnormal mammogram but negative assessment] and the next planned mammogram | 4 years |
| 10- and 15-year breast cancer specific survival in MyPeBS and in a combined analysis of the Wisdom and MyPeBS studies | 15 years |
| Detection rate of stage 2+ breast cancer in women who had screening tomosynthesis (where and when available) and the rate without tomosynthesis | 4 years |
| Incidence of all stage and stage 2 + breast cancers at 10- and 15-year follow-up | 15 years |
| Incidence of stage 2 + breast cancer in each arm, in women aged 40-49 at inclusion | 4 years |
| Rate of breast cancers identified at second reading in each arm | 4 years |
| Rate of false positive imaging findings and benign breast biopsies in women classified at low risk in risk-based arm | 4 years |
| Villejuif |
| France |
| Assuta Medical Center Ramat HaHayal | Tel Aviv | Israel |
| AUSL Reggio Emilia | Reggio Emilia | Emilia-Romagna | Italy |
| Marta Romản | Barcelona | Spain |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge | Cambridgeshire | United Kingdom |
| Derived |
| Roux A, Cholerton R, Sicsic J, Moumjid N, French DP, Giorgi Rossi P, Balleyguier C, Guindy M, Gilbert FJ, Burrion JB, Castells X, Ritchie D, Keatley D, Baron C, Delaloge S, de Montgolfier S. Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial. BMC Cancer. 2022 May 6;22(1):507. doi: 10.1186/s12885-022-09484-6. |
| D055585 |
| Physical Phenomena |